Silence Therapeutics Q3 EPS $(0.24) Misses $(0.12) Estimate
Benzinga Newsdesk 1 week ago
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 46.67 percent increase over losses of $(0.45) per share
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 46.67 percent increase over losses of $(0.45) per share from the same period last year.
